Fermenting milk with two probiotic strains together produced peptides that were better at fighting bacteria, scavenging free radicals, and inhibiting a diabetes-related enzyme than single-strain fermentation.
90.8% enzyme inhibitionConsortium-derived milk peptides blocked α-amylase — an enzyme that breaks down starch into sugar — far more effectively than single-strain peptides
What the researchers found
Fermenting milk with a two-strain probiotic consortium (Bacillus spizizenii and Bacillus subtilis) produced bioactive peptides with markedly enhanced multi-functional activity compared to single-strain fermentation. The consortium peptides achieved 90.80% α-amylase inhibition (relevant to diabetes management), 54.17% ABTS radical scavenging (antioxidant activity), and potent antimicrobial activity with MICs of 2.5–5 µg/mL against five bacterial pathogens including Pseudomonas aeruginosa and Staphylococcus aureus.
Why it matters
Most research on milk-derived bioactive peptides uses single probiotic strains. This study shows that combining two indigenous probiotic strains produces peptides with stronger antidiabetic, antioxidant, and antimicrobial properties than either strain alone — suggesting that multi-strain fermentation could unlock more potent functional foods.
How the study worked
Milk was fermented using either single Bacillus strains or a two-strain consortium. Bioactive peptides (≤10 kDa) were purified from the fermented milk and characterized using reverse-phase HPLC and high-resolution LC-MS/MS. The peptides were then tested for α-amylase inhibition (a marker of antidiabetic potential), ABTS radical scavenging (antioxidant capacity), and antimicrobial activity via minimum inhibitory concentration (MIC) testing against five bacterial species.
Who was studied
In vitro study — no human or animal subjects (tested milk fermented by probiotic bacteria)
What this study cannot tell us
This was entirely an in vitro (lab-based) study — no animal or human testing was conducted. The bioactive peptides were not individually isolated and characterized, so it's unclear which specific peptides are responsible for the observed activities. Bioavailability, digestive stability, and in vivo efficacy remain unknown. The study used specific indigenous Bacillus strains that may not be commercially available.
How to read the evidence
This is an in vitro laboratory study demonstrating bioactivity in test tubes. No animal or human data supports these findings yet, placing this at the earliest stage of evidence for health benefit claims.
When this study was published
Published in 2026, this is very recent research. It represents the cutting edge of multi-strain probiotic fermentation for bioactive peptide production.
The bigger picture
Food-derived bioactive peptides are a growing area of functional food research. This study adds to the evidence that fermentation conditions — particularly which microbes you use — dramatically affect the bioactivity of the peptides produced. Multi-strain consortia could become a standard approach for producing more potent functional dairy products.
Questions still open
- Which specific peptide sequences are responsible for the enhanced bioactivities observed with consortium fermentation?
- Would these peptides survive human digestion and retain their activity after oral consumption?
- Can this multi-strain approach be scaled to commercial dairy fermentation processes?
Common questions
Can drinking probiotic milk give you these health benefits?
Why did two probiotic strains work better than one?
Read the original research
Antioxidant, Antidiabetic, and Antimicrobial Activities of Bioactive Peptides Derived From Milk Fermented by Multi-Strain Probiotic Consortium.
Molecular nutrition & food research, 70(1), e70322
Citation
Maniya, Hina; Singh, Brij Pal; Kumar, Vijay. (2026). Antioxidant, Antidiabetic, and Antimicrobial Activities of Bioactive Peptides Derived From Milk Fermented by Multi-Strain Probiotic Consortium.. Molecular nutrition & food research, 70(1), e70322. https://doi.org/10.1002/mnfr.70322